Management of Cytokine Release Syndrome (CRS) and HLH
Resource type
Book Section
Authors/contributors
- Kröger, Nicolaus (Editor)
- Gribben, John (Editor)
- Chabannon, Christian (Editor)
- Yakoub-Agha, Ibrahim (Editor)
- Einsele, Hermann (Editor)
- Ayuketang, Francis Ayuk (Author)
- Jäger, Ulrich (Author)
Title
Management of Cytokine Release Syndrome (CRS) and HLH
Abstract
Abstract
Cytokine release syndrome (CRS) is caused by a rapid and mild to massive release of cytokines from immune cells involved in immune reactions, particularly after immunotherapy. The frequency and severity of CRS after CAR-T cell therapy varies between products (any grade: 37–93%, G3/4: 1–23%) (Neelapu et al. 2017; Schuster et al. 2019; Abramson et al. 2020).
Book Title
The EBMT/EHA CAR-T Cell Handbook
Date
2022
Publisher
Springer International Publishing
Place
Cham
Pages
135-139
ISBN
978-3-030-94352-3 978-3-030-94353-0
Accessed
10/9/25, 7:44 PM
Language
en
Library Catalog
DOI.org (Crossref)
Extra
Citation
Ayuketang, F. A., & Jäger, U. (2022). Management of Cytokine Release Syndrome (CRS) and HLH. In N. Kröger, J. Gribben, C. Chabannon, I. Yakoub-Agha, & H. Einsele (Eds.), The EBMT/EHA CAR-T Cell Handbook (pp. 135–139). Springer International Publishing. https://doi.org/10.1007/978-3-030-94353-0_26
TEXTBOOKS
CORE CURRICULUM
HEME-ONC AND CELLULAR THERAPIES
Link to this record